Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α

Ling Wang1,2,*
Xue-Min Qiu1,2,*
Yu-Yan Gui1,2
Ying-Ping Xu1,2
Hans-Jürgen Göber3
Da-Jin Li1

1Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, IBS, Fudan University Shanghai Medical College, 2Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, People’s Republic of China; 3Department of Pharmacy, Wagner Jauregg Hospital and Children’s Hospital, Wagner Jauregg Weg, Linz, Austria

*These authors contributed equally to this work

Introduction: Bu-Shen-Ning-Xin decoction (BSNXD) is a traditional Chinese medicinal composition that has been used as a remedy for postmenopausal osteoporosis, but the mechanisms affecting bone metabolism are not fully understood.

Purpose: We investigated the molecular mechanism and signaling pathway underlying the effect of BSNXD on osteoclastogenesis.

Materials and methods: A postmenopausal osteoporosis animal model generated by ovariectomy was administered BSNXD and drug-derived serum was prepared. An enzyme immunoassay was conducted to measure the 17β-estradiol (E2) concentration in the drug-derived serum. Bone marrow-derived monocyte/macrophage precursor cells were treated with drug-derived serum, and tartrate-resistance acid phosphatase staining was conducted to observe osteoclastogenesis. A bone resorption assay was performed to analyze the effect on osteoclastic resorptive function. Real-time PCR, flow cytometry, Western blotting, transfection, and luciferase assays were conducted to explore the related mechanism.

Results: E2 was not elevated in BSNXD-derived serum. BSNXD-derived serum suppressed receptor activation of nuclear factor κB ligand (RANKL)-activated osteoclastogenesis in a dose-dependent manner; this effect could be reversed by estrogen receptor α antagonist methyl-piperidino-pyrazole. The serum suppressed RANKL-induced NF-κB transcription and inhibited the accumulation of nuclear factor of activated T-cells, cytoplasmic 1 in osteoclast precursor cells; the inhibitory effect was abolished by methyl-piperidino-pyrazole but not the estrogen receptor β antagonist or androgen receptor antagonist.

Conclusion: These results collectively suggest that administration of BSNXD presents inhibitory effects on osteoclast differentiation by abrogating the RANKL-induced nuclear factor of activated T-cells, cytoplasmic 1 and NF-κB signaling pathways downstream of estrogen receptor α, thereby contributing to the inhibitory effect on bone resorption.

Keywords: herbal formula, osteoclastogenesis, estrogen receptor α, NF-κB, NFATc1

Introduction

Postmenopausal osteoporosis (PMO) is a major health concern in countries with an aging population (ie, People’s Republic of China) and occurs due to estrogen deprivation postmenopause.1 The balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption is disrupted by estrogen deficiency in favor of increased osteoclast-mediated bone resorption, thereby leading to bone loss.2

Correspondence: Da-Jin Li
Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, IBS, Fudan University Shanghai Medical College, 413 Zhaozhou Road, Shanghai 200001, People’s Republic of China
Tel +86 21 63457331
Email djli@shmu.edu.cn

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy
21 July 2015
Number of times this article has been viewed.
Mature osteoclasts are multinucleated giant cells that play a pivotal role as bone-resorbing cells during bone remodeling by maintaining a balance with bone-forming osteoblasts. Osteoclasts differentiate from hematopoietic stem cells following stimulation by two key factors produced by osteoblasts: macrophage-colony-stimulating factor (M-CSF) and receptor activation of nuclear factor κB ligand (RANKL). Several regulators of osteoclast fate determination and differentiation have been identified, and a variety of transcription factors (ie, nuclear factor of activated T-cells, calcineurin-dependent 1 or NFATc1) seem to be pivotal for osteoclast differentiation.

Increasing estrogen levels in postmenopausal women via estrogen-replacement therapy could prevent postmenopausal bone loss. However, the safety of this practice is controversial. According to the Women’s Health Initiative Study, long-term estrogen replacement causes an unacceptable increase in the risk of various diseases, such as heart attack, stroke, and breast and uterine cancer. Moreover, the recently proposed “critical time window” claimed that use of estrogen after menopause would lead to increased health risks, while using the same during the early menopause transition might be beneficial. Consequently, other potential, effective, and safe therapies need to be examined, including traditional Chinese medicines (TCMs).

Bu-Shen-Ning-Xin decoction (BSNXD) is a type of TCM remedy that has been used for hundreds of years to treat and prevent menopause-related disorders and aging diseases, including PMO. BSNXD consists of drying rehmannia root, common anemarrhena rhizome, bark of the Chinese corktree, barbary wolfberry fruit, Chinese dodder seed, shorthorned epimedium herb, spina date seed, and oriental waterplantain rhizome (Table 1). Although BSNXD has a beneficial action on skeletal mass, the cellular and molecular mechanism mediating this action is not fully understood.

Unlike modern medicine that comprises target-oriented therapeutic interventions, TCMs aim to restore the Yin-Yang balance of body energy using a holistic and synergistic approach so that the body’s normal function and homeostasis can be restored. The hypothesis underlying TCMs is that multiple active phytochemical components in the formulae may simultaneously target multiple molecules/pathways and thereby potentially achieve superior effects compared with

**Table 1** The composition and preparation of the herbal formula BSNXD

<table>
<thead>
<tr>
<th>Crude herbs</th>
<th>Latin names</th>
<th>Content (g)</th>
<th>Main components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drying rehmannia root</td>
<td>Radix Rehmanniae Exsiccata</td>
<td>15</td>
<td>Catalpol13,14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acteoside13,14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Apigenin13,14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sarsasapogein15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Timosaponin15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Markogein15</td>
</tr>
<tr>
<td>Common anemarrhena rhizome</td>
<td>Anemarrhena asphodeloides Bunge</td>
<td>15</td>
<td>Berberine16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phellodendrine16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jatrohizine16</td>
</tr>
<tr>
<td>Bark of Chinese corktree</td>
<td>Phellodendron amurense Rupr.</td>
<td>9</td>
<td>Lycium barbarum polysaccharides (LBP)17</td>
</tr>
<tr>
<td>Barbary Wolfberry fruit</td>
<td>Fructus Lycii barbari</td>
<td>15</td>
<td>β-Carotene27</td>
</tr>
<tr>
<td>Chinese dodder seed</td>
<td>Cuscuta chinensis</td>
<td>12</td>
<td>Quercetin19,19</td>
</tr>
<tr>
<td>Shorthorned epimedium herb</td>
<td>Epimedium brevicomum Maxim</td>
<td>12</td>
<td>Kaempferol18,19</td>
</tr>
<tr>
<td>Spina date seed</td>
<td>Ziziphus jujuba Mill. var. spinosa</td>
<td>9</td>
<td>Hyperoside18,19</td>
</tr>
<tr>
<td>Oriental waterplantain rhizome</td>
<td>Alisma plantago-aquatica Linn.</td>
<td>12</td>
<td>Icarin12,23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Icarin P12,23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Icarin II12,23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jujuboside A12,23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jujuboside A112,23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jujuboside C22,23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alisol A24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alisol B24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alisol C 23 acetate24</td>
</tr>
</tbody>
</table>

**Notes:** The preparation of the herbal formula BSNXD is based on the traditional method. The crude herbs above (×15) were mixed, immersed in deionized water (ten times the herbs’ total weight), and then boiled at 90°C for 60 minutes for the first decoction. An aqueous extract was made by boiling the herbs three times to make a decoction. The three extracts were combined and concentrated by rotary evaporator (Model N1000, Eyela, Japan). The yield of the BSNXD extract was 742.5 mL with 2 g/mL (weight/volume) total raw herbs.

**Abbreviation:** BSNXD, Bu-Shen-Ning-Xin decoction.
single compounds alone. However, the specific mechanisms are always vague.

To investigate the effects of BSNXD on PMO, we used a female mouse ovariectomy (OVX) model to deplete ovarian hormones.\(^{11,12}\) Previously, we prepared pharmacological serum from ovariectomized mice treated with BSNXD and found that BSNXD pharmacological serum promoted proliferation and inhibited apoptosis of mouse osteoblasts through the activation of the MAPK signaling pathways via ERK1/2 phosphorylation.\(^5\) The present study investigated the effects of mid-dose BSNXD-derived serum on murine osteoclastogenesis in vitro from osteoclast precursor cells stimulated with RANKL and M-CSF and explored the involvement of RANKL-induced NFATc1 expression regulation on the effect of BSNXD on osteoclastogenesis.

**Materials and methods**

**Preparation of BSNXD extracts**

The herbal formula of BSNXD is composed of eight crude herbs that are prepared as shown in Table 1.\(^{13–24}\) The rule of compositions comes from traditional Chinese medicinal theory, and the compositions are derived from our clinical experience. The BSNXD was obtained from the pharmacy of the Hospital of Obstetrics and Gynecology, Fudan University, Shanghai, People’s Republic of China. These products were manufactured under good manufacturing practice conditions at the Institute of Obstetrics and Gynecology, Fudan University Shanghai Medical College, according to the protocol described in Chinese Pharmacopoeia 2005\(^25\) with modifications. Crude water extracts were prepared from powdered BSNXD.\(^7,8\)

**Experimental drug administration**

The animal experiments were approved by the experimental animal ethics committee of Fudan University. We used 90 eight-week-old female BALB/c mice with a body mass between 20 g and 30 g purchased from the Laboratory Animal Facility of Chinese Academy of Sciences (Shanghai, People’s Republic of China). All of the mice underwent bilateral oophorectomy. After OVX, the mice were randomly divided into three groups (OVX, OVX + BSNXD mid-dose, and OVX + E2 groups; n=30 mice per group).

The OVX control group received a saline treatment (n=30). The OVX + BSNXD mid-dose group mice were treated with 0.5 mL of evaporated BSNXD extract twice daily (with 1 g/mL, w/v, of the total raw herbs) by oral administration (Table 1); this dosage was ninefold higher than the human adult dose based on an established formula for human–mouse drug conversions (n=30). The OVX + E2 group mice received estrogen (17-β-estradiol, E2) treatment (100 μg/kg per day orally, n=30).\(^{26–29}\) After 4 weeks, all mice were weighed and sacrificed after the last treatment to harvest blood samples. Successful OVX was confirmed by observation of a lack of ovarian tissue and atrophied uterine horns.

**Drug-derived serum preparation and E2 measurement by enzyme immunoassay**

All of the mice were sacrificed after 1 month of treatment, and blood samples were quickly obtained from the mice by cardiac puncture. Blood volumes up to 1 mL have frequently been obtained from mice. Serum samples were prepared by centrifugation. The sera were inactivated at 56°C for 30 minutes, filtered with a 0.2 μm filter, and used at different concentrations. The sera were stored at −20°C for the determination of E2 concentrations or the following experiments. The E2 concentrations in serum samples were measured using the E2 enzyme immunoassay kit following the manufacturer’s protocol (BioCheck Inc., Burlingame, CA, USA).

**Bone marrow isolation and primary osteoclast culture**

Mice in the OVX group were sacrificed by CO2 asphyxiation. For each mouse, the right femurs and tibias were isolated and cleaned by removing any associated muscles or connective tissues with sterile gauze. Bone marrow was flushed from the right femur andibia using a 23 G needle with basal culture medium (Modified Eagle Medium [MEM] without phenol red supplemented with 50 U/mL penicillin and 50 μg/mL streptomycin; Thermo Fisher Scientific, Waltham, MA, USA). Total bone marrow from the right femur andibia of each mouse was pooled and passed through a 40 μm nylon mesh filter to remove any bone particulates. Bone marrow cells were cultured with 10 ng/mL M-CSF (R&D Systems, Minneapolis, MN, USA) for 2 days and used as bone marrow-derived monocyte/macrophage precursor cells (BMMs). BMMs were cultured with 50 ng/mL RANKL (Peprotech, Rocky Hill, NJ, USA) and 10 ng/mL M-CSF for 3 days.\(^{30,31}\) The OVX + BSNXD mid-dose group-derived sera were added to the culture medium (without phenol red) at 10%, 15%, and 20% concentrations. To estimate the effect of OVX + BSNXD group-derived serum on osteoclastogenesis, OVX group-derived BMMs were exposed to serial concentrations of OVX + BSNXD mid-dose group-derived serum or...
OVX + E2 group-derived serum in the presence of RANKL stimulation for 72 hours.

OVX group-derived BMMs were treated with 10⁻⁶ M methyl-piperidino-pyrazole (MPP, estrogen receptor [ER] α antagonist; Tocris Cookson Inc., Ellisville, MO, USA), 10 nM R,R-THC (ERβ antagonist; Tocris Cookson Inc.), or 10 µM flutamide (FLUT, androgen receptor [AR] antagonist; Sigma-Aldrich Co., St Louis, MO, USA) in MEM without phenol red for 1 hour prior to exposure to 20% OVX group-derived serum (control serum) or 20% OVX + BSNXD mid-dose group-derived serum for 72 hours.²⁷,³²,³³ Osteoclastogenesis was evaluated by tartrate-resistance acid phosphatase (TRAP) staining using the Leukocyte Acid Phosphatase Kit (Sigma-Aldrich Co.). TRAP-positive multinucleated cells (TRAP⁺ MNCs; more than five nuclei) were counted microscopically. The results from at least six independent experiments are shown.

Bone resorption assay
BMMs were pretreated with the control or 20% mid-dose BSNXD-derived serum in the presence of RANKL for 48–72 hours to induce osteoclastogenesis on collagen-coated dishes. Then, the mature osteoclasts in each group were harvested by treatment with trypsin-EDTA (Thermo Fisher Scientific, Waltham, MA, USA). The collected cells were seeded and cultured for 2 days on dentin slices treated with 1 M NH₄OH with sonication and stained with 0.5% toluidine blue.²⁴,³⁵

Quantitative real-time PCR
Total RNA was extracted from the control and the various time points of mid-dose BSNXD drug serum-exposed BMMs according to the manufacturer’s instructions (SV Total RNA Isolation System; Promega Corporation, Fitchburg, WI, USA). Quantitative real-time polymerase chain reaction (PCR) amplifications were performed with gene-specific primers using a 7500 real-time PCR System (Thermo Fisher Scientific). The primers for CsF1R, RANK, and β-actin are listed in Table 2. The relative standard curve assay was used to calculate the amplification differences for each primer set. Relative CsF1R or RANK expression levels were obtained from relative standard curves run in triplicate after dividing each value by the β-actin value.

Flow cytometry
Staining for BMM cell surface expression of CsF1R and RANK was performed using monoclonal phycoerythrin-conjugated anti-mouse CD115 (CsF1R), phycoerythrin anti-mouse RANK (CD265), and isotype controls (eBioscience Inc., San Diego, CA, USA) on a FACScan flow cytometer with CellQuest software (BD Biosciences, San Jose, CA, USA).

Transfection and luciferase assay
Transient transfections with NF-κB-luciferase were accomplished using Lipofectamine (Gibco-BRL). The luciferase transfection protocol and luciferase activity assay using the dual luciferase kit (Promega Corporation) and TD-20/20 luminometer (TurnerDesigns, Sunnyvale, CA, USA) have been extensively described.²⁷–⁴⁰ Briefly, OVX group-derived BMMs were transfected with 2 µg of NF-κB-luciferase. A significant RANKL-induced increase in NF-κB-luciferase activity was first detected at 6 hours; similar results were obtained at both the 6 hours and 24 hours time points.⁴⁰ To determine the effects of OVX + BSNXD mid-dose group-derived serum on RANKL-induced NF-κB-luciferase activity, the cells were treated with the indicated agents for 24 hours after transfection. Concentrations of 10⁻⁶ M MPP, 10 nM R,R-THC, or 10 µM FLUT in MEM without phenol red were administered for 1 hour prior to stimulation with 20% OVX group-derived serum (control serum) or 20% OVX + BSNXD mid-dose group-derived serum in the presence of 50 ng/mL RANKL. Cells were harvested 12 hours after treatment; then, cell extracts were prepared and luciferase activities were measured.

Western blot analysis
BMMs were harvested after stimulation with RANKL and M-CSF. The cultures were washed with PBS and lysed with RIPA buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 50 mM β-glycerophosphate, 1% NP-40, 1 mM

Table 2 Sequences of the primers for CsF1R, RANK, and β-actin

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CsF1R</td>
<td>5′-GTC AGA GGC CCC GTT TGT T-3′</td>
<td>5′-AGT AAA TAT AGA GGC TAG CAC TGT GAG AAC-3′</td>
</tr>
<tr>
<td>RANK</td>
<td>5′-ATG GTG GGC TAC CCA GGT GA-3′</td>
<td>5′-ACT TGC GGC TGC ACA GTG A-3′</td>
</tr>
<tr>
<td>β-actin</td>
<td>5′-AGA TGT GGA TCA GCA AGC AG-3′</td>
<td>5′-GCG CAA GTT AGG TTT TGT CA-3′</td>
</tr>
</tbody>
</table>
Na<sub>2</sub>VO<sub>4</sub>, and 1× protease inhibitor cocktail). Total protein content was measured using the Quant-iTTm protein assay kit (Thermo Fisher Scientific; Q32860). The extracted proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrotransferred onto PVDF membranes. The membranes were blocked for 1 hour at room temperature in 5% fat-free milk in Tris-buffered saline and Tween 20 (TBST) buffer (10 mM Tris–HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) with gentle agitation, washed once, and then incubated overnight at 4°C with primary antibodies against phospho-PLCγ2, PLCγ2 (Cell Signaling Technology), NFATc1 (Santa Cruz Biotechnology Inc., Dallas, TX, USA), and β-actin (Santa Cruz Biotechnology Inc.). The blots were washed twice with TBST and incubated for 1 hour at room temperature with horseradish peroxidase-conjugated secondary antibodies (Bio-Rad Laboratories Inc., Hercules, CA, USA; anti-mouse, 170-5047), followed by another round of triple washing. Immunocomplexes were observed by a chemiluminescence reaction with enhanced chemiluminescence reagents (Thermo Fisher Scientific; 34080) and photographed. Then, the membranes were stripped by incubation with stripping solution (Pierce; Dallas, TX, USA), and antibodies against phospho-PLCγ2 or PLCγ2 were used in an additional set of experiments.

Statistical analysis
All values were expressed as the mean ± SEM. Differences between experimental groups were analyzed using ANOVA and the Kruskal–Wallis tests, with P<0.05 considered significant. Data were analyzed using the SPSS software.

Results
The effect of mid-dose BSNXD-derived serum on osteoclastogenesis in vitro
We added the BSNXD drug directly to the culture of murine BMMs in our in vitro experiments but observed no effect on RANKL-induced osteoclastogenesis (data not shown). Therefore, we analyzed the modulation of RANKL-induced osteoclastogenesis by murine mid-dose BSNXD-derived serum. Murine BMMs were incubated with serial concentration of mid-dose BSNXD-derived serum or E2-derived serum in the presence of RANKL and M-CSF and allowed to grow and differentiate into osteoclasts. Our results showed that the mid-dose BSNXD-derived serum decreased the numbers of TRAP-positive multinucleated osteoclasts in a dose-dependent manner (P<0.05 or P<0.01), with maximal effects observed in the 20% mid-dose BSNXD-derived serum; notably, the 20% mid-dose BSNXD-derived serum showed decrease in osteoclastogenesis compared with the 20% E2-derived serum (Figure 1A and B). Neither the 10%–20% mid-dose BSNXD-derived serum nor the E2-derived serum affected the cell viability of BMCs, as determined by the MTT assay (data not shown).

Accordingly, we used the 20% mid-dose BSNXD-derived serum to explore the downstream signaling pathway and molecular mechanisms. To determine whether the ER subtype or AR was involved in the effects of the BSNXD-derived serum, selective ERα, ERβ, and AR antagonists were used in an additional set of experiments.

Pretreatment of BMMs with the selective ERα antagonist (10<sup>−6</sup> M MPP), ERβ antagonist (10 nM R,R-THC), or AR antagonist FLUT (10 μM FLUT) for 1 hour prior to treatment with 20% OVX-derived serum (control serum) for 72 hours did not affect osteoclastogenesis. In contrast, pretreatment of BMMs with 10<sup>−6</sup> M MPP for 1 hour prior to treatment with 20% mid-dose BSNXD-derived serum for 72 hours significantly increased osteoclastogenesis (P<0.01); however, treatment with 10 nM R,R-THC or 10 μM FLUT did not have an effect (Figure 1C). This result suggested that the mid-dose BSNXD-derived serum inhibited osteoclastogenesis via the ERα pathway rather than the ERβ or AR pathways.

BSNXD did not elevate estradiol levels in pharmacological serum
The serum estradiol concentration of OVX mice was significantly lower than the Sham mice (P<0.05; data not shown). Administration of BSNXD to the OVX mice did not significantly change the estradiol concentration in the serum (P>0.05, data not shown).

BSNXD-derived serum suppresses RANKL-induced NF-κB transcription via ERα in osteoclasts
To determine the intracellular signal pathway and transcription factor involved in the action of BSNXD-derived serum, BMMs transfected with NF-κB-luciferase were pretreated with 10<sup>−6</sup> M MPP, 10 nM R,R-THC, or 10 μM FLUT 1 hour prior to the treatment with 20% OVX-derived serum (control serum) or 20% OVX + BSNXD mid-dose group-derived serum in the presence of RANKL. The NF-κB-luciferase activity decreased significantly after treatment with 20% BSNXD-derived serum compared with the 20% control serum (P<0.01); the effect of the BSNXD-derived serum was significantly blocked by the ERα antagonist (MPP) (P<0.01) but not by the ERβ antagonist.
antagonist (R,R-THC) or AR antagonist FLUT. Pretreatment with MPP, R,R-THC, or FLUT prior to treatment with the 20% OVX-derived serum did not affect NF-κB-luciferase activity (Figure 2A). This result suggests that ERα is essential for the suppression of the effect of BSNXD-derived serum on RANKL-induced NF-κB transcription in osteoclasts.

BSNXD-derived serum inhibits RANKL-induced NFATc1 accumulation via the ERα-mediated pathway in osteoclast precursor cells

We investigated the effect of BSNXD-derived serum on RANKL-induced NFATc1 expression and PLC-γ2 phosphorylation during osteoclastogenesis. Exposure to 20% mid-dose BSNXD-derived serum with RANKL treatment did not affect PLC-γ2 phosphorylation during osteoclastogenesis (Figure 2B). Pretreatment with MPP, R,R-THC, or FLUT prior to treatment with the 20% OVX-derived serum did not affect RANKL-induced NFATc1 expression in BMMs. Interestingly, the 20% mid-dose BSNXD-derived serum significantly inhibited RANKL-induced NFATc1 expression in BMMs compared with the control serum (P<0.01). This effect could be abolished by the ERα antagonist (MPP), suggesting that BSNXD downregulated the expression of NFATc1 via ERα signaling pathway (P<0.01). In contrast, the ERβ antagonist (R,R-THC) and AR antagonist FLUT had no significant effect on NFATc1 expression (Figure 2C). These results suggest that this effect involves ERα rather than ERβ or AR.

BSNXD-derived serum does not affect Csf1R and RANK expression during osteoclastogenesis

To investigate whether the BSNXD-induced decrease in osteoclast numbers is due to the downregulation of Csf1R (M-CSF Receptor/CD115) or RANK (RANKL receptor/CD265) expression in osteoclast precursors (OCPs), we examined Csf1R and RANK mRNA and protein levels in OCPs by real-time PCR and flow cytometry, respectively. Bone marrow cells were treated with 20% mid-dose BSNXD-derived serum or control serum, and Csf1R and RANK mRNA and
in vitro. Then, the same number of mature osteoclasts were influenced osteoclast function in vitro. We pretreated BMMs primarily regulated by two signaling pathway: RANKL and M-CSF. Pits) compared with the control (Figure 4A and B). Thus, BSNXD did not present an effect on the osteoclast bone-resorptive function.

**Discussion**

Owing to the arrest of ovarian function after OVX, there is a sudden and dramatic decrease in estrogen production that leads to accelerated bone resorption by increasing osteoclast formation and life spans. Osteoclast differentiation is primarily regulated by two signaling pathway: RANKL and M-CSF. M-CSF promotes the proliferation and survival of BMMs. RANKL is an osteoblast-derived factor that is required for osteoclasts formation; RANKL activates the

BSNXD-derived serum has no effect on the osteoclast bone-resorptive function

Next, we examined whether the BSNXD-derived serum influenced osteoclast function in vitro. We pretreated BMMs with the control or 20% mid-dose BSNXD-derived serum in the presence of RANKL to induce osteoclastogenesis in vitro. Then, the same number of mature osteoclasts were harvested from each group and seeded onto dentin slices. Our results showed that the BSNXD serum did not affect the bone-resorbing activity (ie, the resorption area and osteoclast

protein expression levels were compared between pre- and post-treatment in the presence of RANKL. There were no significant changes in the CSF1R mRNA and protein levels in bone marrow cells after 48 hours of treatment compared with the control (Figure 3A); there were also no differences in the RANK mRNA or protein levels (Figure 3B). These results suggest that the BSNXD-induced osteoclastogenesis inhibition occurs independently of CsflR or RANK in OCPs.

**Figure 2** BSNXD inhibits RANKL-induced NFATc1 accumulation via inhibition of the NF-κB signaling pathway in osteoclast precursor cells. This effect involved estrogen receptor (ER, estrogen receptor; AR, androgen receptor; OVX, ovariectomy; SEM, standard error of the mean; MPP, methyl-piperidino-pyrazole; FLUT, flutamide.

**Notes:** (A) Treatment with the 20% OVX + BSNXD mid-dose group-derived serum significantly decreased NF-xB-luciferase activity compared with treatment with 20% control serum; pretreatment with the selective ERα antagonist (MPP) but not the ERβ antagonist (R,R-THC) or AR antagonist flutamide (FLUT) blocked the effect induced by the BSNXD-derived serum. (B) The ratio of phospho-PLCγ2/total PLCγ2 remained similar during osteoclastogenesis in the different groups. (C) Treatment with 20% OVX + BSNXD mid-dose group-derived serum inhibited RANKL-induced NFATc1 expression in osteoclast precursor cells. This effect involved ERα but not ERβ or AR. "•" represents containing; "−" represents not containing. Data are expressed as means ± SEM (n = 10). **P < 0.01.

**Abbreviations:** BSNXD, Bu-shen-ning-Xin decoction; RANKL, receptor activation of nuclear factor κB ligand; NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; ER, estrogen receptor; AR, androgen receptor; OVX, ovariectomy; SEM, standard error of the mean; MPP, methyl-piperidino-pyrazole; FLUT, flutamide.
differentiation process by inducing NFATc1, the master transcription factor for osteoclastogenesis.\(^4\)

After oral administration of BSNXD, the compounds are absorbed into the bloodstream and become active compounds. The compounds may become functional by oxidation, hydrolysis, or reduction; primary metabolites may also undergo conjugation reactions to form secondary metabolites.\(^45,46\) The serum effect on osteoclasts was dose-dependent and suppressed osteoclast differentiation with no effect on osteoclast viability. Our data also showed that the estrogen level in the BSNXD-derived serum was comparable with the control serum. However, the BSNXD-derived serum was not due to toxic effects on osteoclasts or the elevation of serum E2 levels.

Analysis of the bone phenotype in ER\(\alpha^{-/-}\), ER\(\beta^{-/-}\), and ER\(\alpha\beta^{-/-}\)mice revealed that both receptor subtypes participated in the control of bone turnover in females.\(^47\) In male mice, estradiol regulates trabecular bone remodeling exclusively through ER\(\alpha\), while in females, both ER subtypes influence bone turnover and trabecular structure. OVX of ER\(\beta^{-/-}\)and wild-type mice led to the loss of trabecular bone mineral density, implying that ER\(\alpha\) played an important role in maintaining bone integrity and homeostasis.\(^48\) Therefore, ER\(\alpha\) is the main mediator of the protective effects of estradiol in bone. Indeed, ER\(\alpha^{-/-}\)mice have a low trabecular bone mass.\(^49\) Estradiol prevented ovariectomy-induced bone...
The loss in ERβ−/− mice to levels similar to those observed in wild-type males and females, indicating that ERα was the major mediator of estradiol effects in bone. Furthermore, the evidence that ERα activation due to a rare genetic mutation leads to severe osteoporosis in humans has confirmed that ERα plays an important role in sustaining bone homeostasis.

MPP is a nonsteroidal, pyrazole compound that contains a basic side-chain addition that is reported to convert the pyrazole from an ERα agonist to an ERα antagonist. Co-transfection and in vitro binding assays demonstrated that MPP displayed a 200-fold preferential binding affinity for ERα compared with ERβ. Moreover, an additional in vitro study showed that MPP functioned as an ERα-selective antagonist for estrogen-regulated genes. R,R-THC is an agonist for ERα but a full antagonist for ERβ. The relative potency of R,R-THC in ERα and ERβ transcription assays correlates rather well with its relative affinity in ligand binding assays: it has a higher affinity for ERβ, which is consistent with its greater potency as an ERβ antagonist than an ERα agonist. An ERβ-selective antagonist (R,R-THC) could be used to identify ERβ-mediated activity in animals based on their selective suppression by this ligand. Flutamide, a silent antagonist of AR, competes with testosterone and its powerful metabolite dihydrotestosterone for binding to ARs and is primarily used to treat prostate cancer. FLUT could be used to identify AR-mediated activity in cells based on its suppression by this ligand.

Our data showed that the suppressive effect of BSNXD-derived serum on RANKL-induced osteoclastogenesis occurred via the ERα but not the ERβ or AR pathways. In the present study, we found no differences in bone-resorbing activity of mature osteoclasts after treatment with BSNXD-derived serum or control serum. Therefore, BSNXD does not have an effect on the resorptive function of mature osteoclasts. CSF1R (the receptor for M-CSF) is an essential survival factor for OCPs. M-CSF/CSF1R signaling drives the differentiation of monocytes into macrophages or osteoclasts. CSF1R also acts as a potent stimulator of RANK expression. Because CSF1R and RANK are both expressed on OCPs, one may expect that BSNXD inhibited osteoclastogenesis via downregulating RANK and CSF1R expression in the OCPs, and thereby decreasing the sensitivity of precursor.
cells to RANK and M-CSF. However, we did not observe any changes in the expression of RANK (RANKL receptor/CD265) and CSF1R (M-CSF Receptor/CD115) in the OCPs. Thus, the inhibition of osteoclastogenesis by BSNXD did not result from the decrease of the Csfr1R+ RANK + OCP. Osteoclast formation and functions are mediated by RANKL-induced NF-κB activation. NF-κB is considered to be one of the essential transcription factors for osteoclastogenesis because inhibition of this transcription factor or other proteins in the NF-kB signaling pathway results in the absence or significant reduction of osteoclast formation. Therefore, the inhibition of RANKL-induced NF-κB activity might be an effective approach to target osteoclastogenesis and treat osteoporosis. The results from the present study revealed that BSNXD-derived serum inhibited RANKL-induced NF-κB activity during osteoclastogenesis in an ERα-dependent manner.

Binding of RANKL–RANK also activates transcription factor NFATc1, which is a master regulator of osteoclastogenesis, and then directs the expression of osteoclast-specific genes. Our data revealed that the suppression of RANKL-induced activation of NFATc1 via the ERα pathway by BSNXD was correlated with its inhibition of osteoclastogenesis. In our study, the attenuation of the NF-kB signaling pathway downstream of ERα may correspond to a mechanism that contributes to the suppression of NFATc1 expression by BSNXD. Thus, the mechanism that mediates the anti-osteoclastogenic roles of BSNXD may be the abrogation of RANKL-induced NFATc1 expression via inhibition of the NF-kB signaling pathway downstream of ERα (Figure 5).

Figure 5 Summary of the inhibitory effects of BSNXD on osteoclast differentiation.
Notes: The suppression of BSNXD on RANKL-induced activation of the NFATc1 via ERα pathway is correlated with the inhibition of osteoclastogenesis. The attenuation of the ERα-dependent NF-kB signaling pathway may correspond to a mechanism that contributes to the suppression of NFATc1 expression by BSNXD.
Abbreviations: BSNXD, Bu-Shen-Ning-Xin decoction; RANKL, receptor activation of nuclear factor κB ligand; ER, estrogen receptor; NFATc1, nuclear factor of activated T-cells, cytoplasmic 1; M-CSF, macrophage-colony-stimulating factor.
Conclusion

In conclusion, this study revealed that the inhibitory effects of BSNXD on osteoclast differentiation were related to the abrogation of RANKL-induced NFATc1 expression via inhibition of the ERα-dependent NF-κB signaling pathway in a holism manner. This finding suggests that this TCM remedy is a good approach to treat PMO.

Acknowledgments

This work was supported by the Science and Technology Commission of Shanghai Municipality 2015 YIXUEYINGDAO project, No 15401932200 (to L Wang), the FY2008 JSPS Postdoctoral Fellowship Researchers P08471 (to L Wang), National Natural Science Foundation of China No 30801502 (to L Wang), Shanghai Pujiang Program No 11PJ1401900 (to L Wang), National Natural Science Foundation of China No 81401171 (to X-M Qiu) and Program for Outstanding Medical Academic Leader (to D-J Li).

Disclosure

The authors report no conflicts of interest in this work.

References


